Jan 16, 2018 8:00am EST Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy
Apr 04, 2017 8:00am EDT Key pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications
Mar 13, 2017 6:00am EDT Benitec Biopharma completes second tranche placement to Nant Capital to raise A$5.45 million
Feb 16, 2017 8:00am EST Benitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China
Jan 30, 2017 8:00am EST Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with Nant Capital
Jan 17, 2017 5:00am EST Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy